Steroid-responsive interstitial pneumonitis after fludarabine therapy.
Levin
M
M
Aziz
M
M
Opitz
L
L
D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D003371:Cough / Q000139:chemically induced; D017809:Fatal Outcome; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy; D017563:Lung Diseases, Interstitial / Q000139:chemically induced / Q000188:drug therapy*; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D011239:Prednisolone / Q000627:therapeutic use*; D011241:Prednisone / Q000627:therapeutic use*; D012128:Respiratory Distress Syndrome / Q000139:chemically induced; D012131:Respiratory Insufficiency / Q000139:chemically induced; D014740:Vidarabine / Q000009:adverse effects / Q000031:analogs & derivatives*
D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D005938:Glucocorticoids; D011239:Prednisolone; D014740:Vidarabine; C024352:fludarabine; D011241:Prednisone